*ALERT - ON HOLD* FDA Patient-Focused Drug Development (PFDD) program
Date and time is TBD - ON HOLD
|Virtual Meeting
The National Organization for Rare Disorders (NORD) and the PAP Foundation are hosting a virtual meeting under the FDA's externally led Patient-Focused Drug Development (PFDD) program. The goals of this EL-PFDD meeting are to provide researchers, drug developers and U.S. Food and Drug Administration


Time & Location
Date and time is TBD - ON HOLD
Virtual Meeting
About the event
Are you a patient or caregiver for an individual living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)? Join us on February 5th to participate in the largest-ever virtual meeting of the aPAP community and help us accelerate research by sharing your experiences.Â
Â
The National Organization for Rare Disorders (NORD) and the PAP Foundation are hosting a virtual meeting under the FDA's externally led Patient-Focused Drug Development (PFDD) program. The goals of this EL-PFDD meeting are to provide researchers, drug developers and U.S. Food and Drug Administration (FDA) with an understanding of patients’ and caregivers’ experiences with aPAP, including how people view their quality of life, which aspects of the disease are most problematic, and what actions they currently perform to treat and cope with this disease.Â
Â
LEARN MORE ANDÂ REGISTER HERE
Â